| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3877 | Ofh244 | Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist |
|
| DCC3878 | Ofh3911 | Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist |
|
| DCC3879 | Ofh3912 | Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist |
|
| DCC3880 | Og488-bapta-1-am | Cell-permeable, fluorescent Ca2+ indicator |
|
| DCC3881 | Oga-in-5i | Novel potent O-GlcNAcase (OGA) inhibitor (IC 50 : 46 nM), increasing the level of O-GlcNAcylated protein in cells and displaying suitable pharmacokinetic properties and brain permeability |
|
| DCC3882 | Ohinitib | Novel HSF1 inhibitor for target-based cancer therapy |
|
| DCC3883 | Oh-nplh2 | Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo |
|
| DCC3884 | Oicr766a | Novel Bax activator, having greatest effect enhancing the pro-apoptotic activity of Bax with EC50 values of ∼0.1 μM and ∼0.9 μM, respectively, inducing cell death by a Bax/Bak-dependent mechanism |
|
| DCC3885 | Ojak-989 | Novel orally bioavailable potent JAK-1 inhibitor |
|
| DCC3886 | Okadaic Acid | Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3887 | Okadaic Acid Potassium Salt | Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3888 | Okadaic Acid Sodium Salt | Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3889 | Olanzapine Pamoate | Dopamine antagonist as an atypical antipsychotic |
|
| DCC3890 | Olanzapine/samidorphan | Combination of the atypical antipsychotic olanzapine and opioid receptor antagonist samidorphan for treatment of adults with schizophrenia or bipolar I disorder |
|
| DCC3891 | Oleanonic Acid | Natural inhibitor of the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site, reducing the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes, ameliorating pressure overload-induced cardiac hypertrophy |
|
| DCC3892 | Oleracein E | Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt |
|
| DCC3893 | Olfr895-agonist-10 | Novel specific agonist of odorant receptor 895 (Olfr895) |
|
| DCC3894 | Olmutinib Hydrochloride | Novel Bruton's tyrosine kinase inhibitor, suppressing B cell and monocyte activation and ameliorates arthritis in a mouse model |
|
| DCC3895 | Olprinone | Phosphodiesterase III inhibitor, augmenting cerebral blood flow by a direct vasodilator effect on cerebral arteries |
|
| DCC3896 | Omdm-188 | Novel potent DAGL inhibitor, inhibiting collagen-, but not arachidonic acid-induced aggregation and TxA2 synthesis |
|
| DCC3897 | On012380 | Non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I |
|
| DCC3898 | Oncrasin-72 | Potent analogue of oncrasin-1 with antitumor activity mediated by JNK activation and STAT3 inhibition |
|
| DCC3899 | Ono12380 | Novel non-ATP-competitive inhibitor of BCR-ABL, overriding imatinib resistance |
|
| DCC3900 | Ono-2910 | Novel enhancer of Schwann cell differentiation for treatment of peripheral nerve disorder |
|
| DCC3901 | Ono-3307 | Protease inhibitor |
|
| DCC3902 | Ono-4007 | Lipid A analog, inducing Th1-type immune response in tumor eradication and restoring nitric oxide production by peritoneal macrophages |
|
| DCC3903 | Ono-4310321 | Potent, orally available dual CysLT1 and CysLT2 receptor antagonist |
|
| DCC3904 | Ono-ae1-259 | Highly selective agonist of prostaglandin E2 receptor (EP2) |
|
| DCC3905 | Ono-ae1-259 Lysine | Novel selective EP2 receptor agonist, inducing relaxation of smooth muscle |
|
| DCC3906 | Ono-ae1-329 | Novel agonist of the prostaglandin PGE2 receptor EP4 |
|
